Therapeutic Effects of Coenzyme Q10and Remacemide in Transgenic Mouse Models of Huntington's Disease

The Mouse Brain in Stereotaxic Coordinates

Paxinos, G. (2001) · Cited by 12,859

A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes

MACDONALD, M. (1993) · Cell · doi:10.1016/0092-8674(93)90585-e · Cited by 8,366

mouse brain in stereotaxic coordinates

Franklin, K. B. J., & Paxinos, G. (1997) · Cited by 3,258

Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice

Mangiarini, L., Sathasivam, K., Seller, M., Cozens, B., Harper, A., Hetherington, C., Lawton, M., Trottier, Y., Lehrach, H., Davies, S. W., et al. (1996) · Cell · doi:10.1016/s0092-8674(00)81369-0 · Cited by 3,073

A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. The Huntington's Disease Collaborative Research Group.

Shah, M. A., Datson, N. A., Srinidhi, L., Stanton, V. P., MacDonald, M. E., Allard, M. W., Youngman, S., Am, F., Mott, R., Draths, K., et al. (1993) · Cell · Cited by 3,055

Formation of Neuronal Intranuclear Inclusions Underlies the Neurological Dysfunction in Mice Transgenic for the HD Mutation

Davies, S. W., Turmaine, M., Cozens, B. A., DiFiglia, M., Sharp, A. H., Ross, C. A., Scherzinger, E., Wanker, E. E., Mangiarini, L., & Bates, G. P. (1997) · Cell · doi:10.1016/s0092-8674(00)80513-9 · Cited by 2,188

Replication of the neurochemical characteristics of Huntington's disease by quinolinic acid

Beal, M. F., Kowall, N. W., Ellison, D. W., Mazurek, M. F., Swartz, K. J., & Martin, J. B. (1986) · Nature · doi:10.1038/321168a0 · Cited by 1,287

Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease

Chen, M., Ona, V. O., Li, M., Ferrante, R. J., Fink, K., Zhu, S., Bian, J., Guo, L., Farrell, L. A., Hersch, S. M., et al. (2000) · Nature Medicine · doi:10.1038/77528 · Cited by 1,060

Neurochemical and histologic characterization of striatal excitotoxic lesions produced by the mitochondrial toxin 3-nitropropionic acid

Beal, M. F., Brouillet, E., Jenkins, B. G., Ferrante, R. J., Kowall, N. W., Miller, J., Storey, E., Srivastava, R., Rosen, B. R., & Hyman, B. T. (1993) · Journal of Neuroscience · doi:10.1523/jneurosci.13-10-04181.1993 · Cited by 1,026

Oxidative damage and metabolic dysfunction in Huntington's disease: Selective vulnerability of the basal ganglia

Browne, S. E., Bowling, A. C., Macgarvey, U., Baik, M. J., Berger, S. C., Muquit, M. M. K., Bird, E. D., & Beal, M. F. (1997) · Annals of Neurology · doi:10.1002/ana.410410514 · Cited by 885

Normal Aging Modulates the Neurotoxicity of Mutant Huntingtin

Diguet, E., Petit, F., Escartin, C., Cambon, K., Bizat, N., Dufour, N., Hantraye, P., Déglon, N., & Brouillet, E. (2009) · PLoS ONE · doi:10.1371/journal.pone.0004637 · Cited by 40

Huntington's disease: progress and potential in the field

Stack, E. C., & Ferrante, R. J. (2007) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.16.12.1933 · Cited by 39

RNAi: a potential therapy for the dominantly inherited nucleotide repeat diseases

Denovan‐Wright, E. M., & Davidson, B. L. (2005) · Gene Therapy · doi:10.1038/sj.gt.3302664 · Cited by 37

Prostaglandin E2 EP1 Receptor Antagonist Improves Motor Deficits and Rescues Memory Decline in R6/1 Mouse Model of Huntington's Disease

Anglada‐Huguet, M., Xifró, X., Giralt, A., Zamora‐Moratalla, A., Martín, E. D., & Alberch, J. (2013) · Molecular Neurobiology · doi:10.1007/s12035-013-8556-x · Cited by 40

Mouse Models of Polyglutamine Diseases in Therapeutic Approaches: Review and Data Table. Part II

Switonski, P. M., Szlachcic, W. J., Gabka, A., Krzyżosiak, W. J., & Figiel, M. (2012) · Molecular Neurobiology · doi:10.1007/s12035-012-8316-3 · Cited by 38

Neuroprotective effects of the mGlu5R antagonist MPEP towards quinolinic acid‐induced striatal toxicity: involvement of pre‐ and post‐synaptic mechanisms and lack of direct NMDA blocking activity

Popoli, P., Pintor, A., Tebano, M. T., Frank, C., Pepponi, R., Nazzicone, V., Grieco, R., Pèzzola, A., Reggio, R., Minghetti, L., et al. (2004) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2004.02448.x · Cited by 37

Therapeutic Effects of Anthocyanins and Environmental Enrichment in R6/1 Huntington’s Disease Mice

Kreilaus, F., Spiro, A. S., Hannan, A. J., Garner, B., & Jenner, A. M. (2016) · Journal of Huntington s Disease · doi:10.3233/jhd-160204 · Cited by 38

A tRNATRP gene mediates the suppression of cbs2-223 previously attributed to ABC1/COQ8

Hsieh, E. J., Dinoso, J. B., & Clarke, C. F. (2004) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2004.03.096 · Cited by 37

Dithiol-based Compounds Maintain Expression of Antioxidant Protein Peroxiredoxin 1 That Counteracts Toxicity of Mutant Huntingtin

Pitts, A., Dailey, K. M., Newington, J. T., Chien, A., Arseneault, R., Cann, T., Thompson, L. M., & Cumming, R. C. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.334565 · Cited by 35

From chemical to drug: neurodegeneration drug screening and the ethics of clinical trials

Heemskerk, J., Tobin, A. J., & Ravina, B. M. (2002) · Nature Neuroscience · doi:10.1038/nn931 · Cited by 36

Evidence for behavioral benefits of early dietary supplementation with CoEnzymeQ10 in a slowly progressing mouse model of Huntington's disease

Hickey, M. A., Zhu, C., Medvedeva, V. P., Franich, N. R., Levine, M. S., & Chesselet, M. (2011) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2011.10.007 · Cited by 35

New Directions in Therapeutics for Huntington Disease

Potkin, K. T., & Potkin, S. G. (2018) · Future Neurology · doi:10.2217/fnl-2017-0035 · Cited by 36

Mitochondrial and Redox-Based Therapeutic Strategies in Huntington's Disease

Fão, L., & Rego, A. C. (2020) · Antioxidants and Redox Signaling · doi:10.1089/ars.2019.8004 · Cited by 37

Ubiquinone-10 Production Using Agrobacterium tumefaciens dps Gene in Escherichia coli by Coexpression System

Zhang, D., Shrestha, B., Li, Z., & Tan, T. (2007) · Molecular Biotechnology · doi:10.1385/mb:35:1:1 · Cited by 35

Coenzyme Q and protein/lipid oxidation in a BSE-infected transgenic mouse model

Martin, S. F., Burón, I., Espinosa, J. C., Castilla, J., Villalba, J. M., & Torres, J. M. (2007) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2007.03.005 · Cited by 35

Systemic delivery of P42 peptide: a new weapon to fight Huntington¿s disease

Arribat, Y., Talmat-Amar, Y., Paucard, A., Lesport, P., Bonneaud, N., Bauer, C., Bec, N., Parmentier, M., Benigno, L., Larroque, C., et al. (2014) · Acta Neuropathologica Communications · doi:10.1186/s40478-014-0086-x · Cited by 37

Emerging drug therapies in Huntington's disease

Mason, S., & Barker, R. A. (2009) · Expert Opinion on Emerging Drugs · doi:10.1517/14728210902918299 · Cited by 35

Modulation of NMDA receptor at the synapse: Promising therapeutic interventions in disorders of the nervous system

Mellone, M., & Gardoni, F. (2013) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2013.04.054 · Cited by 38

Energy dysfunction in Huntington’s disease: insights from PGC-1α, AMPK, and CKB

Ju, T., Lin, Y., & Chern, Y. (2012) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-012-1025-2 · Cited by 34

Prostaglandin E2 EP2 activation reduces memory decline in R6/1 mouse model of Huntington's disease by the induction of BDNF-dependent synaptic plasticity

Anglada‐Huguet, M., Vidal-Sancho, L., Giralt, A., Barriga, G. G.-D., Xifró, X., & Alberch, J. (2015) · Neurobiology of Disease · doi:10.1016/j.nbd.2015.09.001 · Cited by 34

Boosting mitochondrial health to counteract neurodegeneration

Burtscher, J., Romani, M., Bernardo, G., Popa, T., Ziviani, E., Hummel, F. C., Sorrentino, V., & Millet, G. P. (2022) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2022.102289 · Cited by 36

Novel therapeutic targets for Huntington’s disease

Hannan, A. J. (2005) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.9.4.639 · Cited by 32

Latrepirdine, a potential novel treatment for Alzheimer's disease and Huntington's chorea.

Sabbagh, M. N., & Shill, H. A. (2010) · PubMed · Cited by 32

Hyperhomocysteinaemia in treated patients with Huntington's disease homocysteine in HD

Andrich, J., Carsten Saft, C., Arz, A., Schneider, B., Agelink, M. W., Kraus, P. H., Kuhn, W., & Müller, T. H. (2003) · Movement Disorders · doi:10.1002/mds.10629 · Cited by 32

Towards a comprehensive understanding of the contributions of mitochondrial dysfunction and oxidative stress in the pathogenesis and pathophysiology of Huntington's disease

Tobore, T. O. (2019) · Journal of Neuroscience Research · doi:10.1002/jnr.24492 · Cited by 32

Coenzyme Q10 serum levels in Huntington’s disease

Andrich, J., Carsten Saft, C., Gerlach, M., Schneider, B., Arz, A., Kuhn, W., & Müller, T. (2004) · Journal of neural transmission. Supplementum · doi:10.1007/978-3-7091-0579-5_13 · Cited by 31

Modeling mitochondrial dysfunctions in the brain: from mice to men

Breuer, M. E., Willems, P. H. G. M., Rüssel, F. G. M., Koopman, W. J. H., & Smeitink, J. A. M. (2011) · Journal of Inherited Metabolic Disease · doi:10.1007/s10545-011-9375-8 · Cited by 30

Advancing pharmacotherapy for treating Huntington’s disease: a review of the existing literature

Mason, S., & Barker, R. A. (2015) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2016.1109630 · Cited by 30

The Effects of Topical Coenzyme Q10 and Vitamin E d -α-Tocopheryl Polyethylene Glycol 1000 Succinate after Cataract Surgery: A Clinical and in vivo Confocal Study

Fogagnolo, P., Sacchi, M. M., Ceresara, G., Paderni, R., Lapadula, P., Orzalesi, N., & Rossetti, L. M. (2012) · Ophthalmologica · doi:10.1159/000342196 · Cited by 30

Diet supplement CoQ10 delays brain atrophy in aged transgenic mice with mutations in the amyloid precursor protein: An in vivo volume MRI study

Li, G., Jack, C. R., Yang, X., & Yang, E. S. (2008) · BioFactors · doi:10.1002/biof.5520320120 · Cited by 30

Targeting mitochondria in the regulation of neurodegenerative diseases: A comprehensive review

Maurya, S. K., Gupta, S., Bakshi, A., Kaur, H., Jain, A., Senapati, S., & Baghel, M. S. (2022) · Journal of Neuroscience Research · doi:10.1002/jnr.25110 · Cited by 31

Excitotoxicity in Huntington disease

Raymond, L. A. (2003) · Clinical Neuroscience Research · doi:10.1016/s1566-2772(03)00054-9 · Cited by 31

Emerging chemotherapeutic strategies for Huntington’s disease

Ryu, H., & Ferrante, R. J. (2005) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.10.2.345 · Cited by 30

Spatiotemporal mapping of brain atrophy in mouse models of Huntington's disease using longitudinal in vivo magnetic resonance imaging

Aggarwal, M., Duan, W., Hou, Z., Rakesh, N., Peng, Q., Ross, C. A., Miller, M. I., Mori, S., & Zhang, J. (2012) · NeuroImage · doi:10.1016/j.neuroimage.2012.01.141 · Cited by 28

Mitochondrial targeted antioxidants as potential therapy for huntington’s disease

Upadhayay, S., & Kumar, P. (2024) · Pharmacological Reports · doi:10.1007/s43440-024-00619-z · Cited by 30

Coenzyme Q10 and its effects in the treatment of neurodegenerative diseases

dos Santos, G. C., Antunes, L. M. G., dos Santos, A. C., & Bianchi, M. D. L. P. (2009) · Brazilian Journal of Pharmaceutical Sciences · doi:10.1590/s1984-82502009000400002 · Cited by 28

Dysregulation of system xc− expression induced by mutant huntingtin in a striatal neuronal cell line and in R6/2 mice

Frederick, N. M., Bertho, J., Patel, K. K., Petr, G. T., Bakradze, E., Smith, S. B., & Rosenberg, P. A. (2014) · Neurochemistry International · doi:10.1016/j.neuint.2014.06.017 · Cited by 27

Unexpected off-targeting effects of anti-huntingtin ribozymes and siRNA in vivo

Denovan‐Wright, E. M., Rodríguez-Lebrón, E., Lewin, A. S., & Mandel, R. J. (2007) · Neurobiology of Disease · doi:10.1016/j.nbd.2007.11.003 · Cited by 27

Proteomic changes in the brains of Huntington's disease mouse models reflect pathology and implicate mitochondrial changes

Deschepper, M., Hoogendoorn, B., Brooks, S. P., Dunnett, S. B., & Jones, L. (2011) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2011.01.012 · Cited by 27

Oral creatine supplementation attenuates L-DOPA-induced dyskinesia in 6-hydroxydopamine-lesioned rats

Valastro, B., Dekundy, A., Danysz, W., & Quack, G. (2008) · Behavioural Brain Research · doi:10.1016/j.bbr.2008.08.004 · Cited by 27

Phenotypes and fed-batch fermentation of ubiquinone-overproducing fission yeast using ppt1 gene

Zhang, D., Shrestha, B., Niu, W. L., Tian, P., & Tan, T. (2006) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2006.09.012 · Cited by 27

Neurodegenerative Diseases: New Hopes and Perspectives

Bhat, M. A., & Dhaneshwar, S. S. (2023) · Current Molecular Medicine · doi:10.2174/1566524023666230907093451 · Cited by 29

Environmental stimulation in Huntington disease patients and animal models

Novati, A., Nguyen, H. P., & Schulze-Hentrich, J. M. (2022) · Neurobiology of Disease · doi:10.1016/j.nbd.2022.105725 · Cited by 29

Targeting aggregation in the development of therapeutics for the treatment of Huntington?s disease and other polyglutamine repeat diseases

Steffan, J. S., & Thompson, L. M. (2003) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.7.2.201 · Cited by 26

Effect of Ubiquinol on Glaucomatous Neurodegeneration and Oxidative Stress: Studies for Retinal Ganglion Cell Survival and/or Visual Function

Edwards, G., Lee, Y., Kim, M., Bhanvadia, S., Keun-young Kim, A., & Ju, W. (2020) · Antioxidants · doi:10.3390/antiox9100952 · Cited by 25

Ubisol-Q10, a Nanomicellar and Water-Dispersible Formulation of Coenzyme-Q10 as a Potential Treatment for Alzheimer’s and Parkinson’s Disease

Wear, D., Vegh, C., Sandhu, J. K., Sikorska, M., Cohen, J., & Pandey, S. (2021) · Antioxidants · doi:10.3390/antiox10050764 · Cited by 16

Involvement of Coenzyme Q10 in Various Neurodegenerative and Psychiatric Diseases

Ebrahimi, A., Kamyab, A., Hosseini, S., Ebrahimi, S., & Ashkani‐Esfahani, S. (2023) · Biochemistry Research International · doi:10.1155/2023/5510874 · Cited by 29

Neuroprotective effect of Coenzyme Q10 on ischemic hemisphere in aged mice with mutations in the amyloid precursor protein

Li, G., Zou, L., Jack, C. R., Yang, Y., & Yang, E. S. (2006) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2006.05.005 · Cited by 25

Coenzyme Q10 protects Pc12 cells from cisplatin-induced DNA damage and neurotoxicity

Machado, C. D. S., Mendonça, L. M., Venâncio, V. P., Bianchi, M. L. P., & Antunes, L. M. G. (2013) · NeuroToxicology · doi:10.1016/j.neuro.2013.02.004 · Cited by 24

RNAi Therapy for Neurodegenerative Diseases

Boudreau, R. L., & Davidson, B. L. (2006) · Current topics in developmental biology/Current Topics in Developmental Biology · doi:10.1016/s0070-2153(06)75003-7 · Cited by 24

Huntington's disease

Hersch, S. M. (2003) · Current Opinion in Neurology · doi:10.1097/01.wco.0000084229.82329.03 · Cited by 23

Amitriptyline Improves Motor Function via Enhanced Neurotrophin Signaling and Mitochondrial Functions in the Murine N171-82Q Huntington Disease Model

Cong, W., Chadwick, W., Wang, R., Daimon, C. M., Cai, H., Amma, J., Wood, W. H., Becker, K. G., Martin, B., & Maudsley, S. R. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.588608 · Cited by 22

EFFECT OF MELATONIN COTREATMENT AGAINST KAINIC ACID ON COENZYME Q10, LIPID PEROXIDATION AND TRX mRNA IN RAT HIPPOCAMPUS

Yalçın, A., Kilinç, E., Koçtürk, S., Resmi, H., & Sözmen, E. Y. (2004) · International Journal of Neuroscience · doi:10.1080/00207450490475535 · Cited by 22

Protective Efficacy of Coenzyme Q10 Against DDVP-Induced Cognitive Impairments and Neurodegeneration in Rats

Binukumar, B. K., Gupta, N., Sunkaria, A., Kandimalla, R. J. L., Wani, W. Y., Sharma, D. R., Bal, A., & Gill, K. D. (2011) · Neurotoxicity Research · doi:10.1007/s12640-011-9289-0 · Cited by 22

Indoleamine 2,3-dioxygenase as a novel therapeutic target for Huntington’s disease

Boros, F. A., Klivènyi, P., Toldi, J., & Vécsei, L. (2018) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2019.1549231 · Cited by 20

Lack of efficacy of NMDA receptor-NR2B selective antagonists in the R6/2 model of Huntington disease

Tallaksen‐Greene, S. J., Janiszewska, A., Benton, K., Ruprecht, L., & Albin, R. L. (2010) · Experimental Neurology · doi:10.1016/j.expneurol.2010.07.015 · Cited by 22

Coenzyme Q and the regulation of intracellular steady‐state levels of superoxide in HL‐60 cells

González‐Aragón, D., Burón, M. I., López‐Lluch, G., Herman, M. D., Gómez-Dı́az, C., Navas, P., & Villalba, J. M. (2005) · BioFactors · doi:10.1002/biof.5520250105 · Cited by 21

Discovery of Therapeutic Approaches for Polyglutamine Diseases: A Summary of Recent Efforts

Esteves, S., Duarte‐Silva, S., & Maciel, P. (2016) · Medicinal Research Reviews · doi:10.1002/med.21425 · Cited by 22

Altered Aconitase 2 Activity in Huntington’s Disease Peripheral Blood Cells and Mouse Model Striatum

Chen, C., Wu, Y., & Chang, K. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18112480 · Cited by 20

Molecular biology of Huntington's disease

McFarland, K. N., & Cha, J.-H. J. (2011) · Handbook of clinical neurology · doi:10.1016/b978-0-444-52014-2.00003-3 · Cited by 21

A mitochondrial basis for Huntington’s disease: therapeutic prospects

Chakraborty, J., Rajamma, U., & Mohanakumar, K. P. (2013) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-013-1951-9 · Cited by 21

MRI of mouse models of neurological disorders

Anderson, S. A., & Frank, J. A. (2007) · NMR in Biomedicine · doi:10.1002/nbm.1167 · Cited by 20

Exploring Molecular Approaches in Amyotrophic Lateral Sclerosis: Drug Targets from Clinical and Pre-Clinical Findings

Alam, M., Yadav, R. K., Minj, E., Tiwari, A., & Mehan, S. (2020) · Current Molecular Pharmacology · doi:10.2174/1566524020666200427214356 · Cited by 21

Mouse Models of Triplet Repeat Diseases

Bates, G. P., & Gonitel, R. (2006) · Molecular Biotechnology · doi:10.1385/mb:32:2:147 · Cited by 20

Mesenchymal Stem Cell Therapy for Huntington Disease: A Meta-Analysis

Liang, X.-S., Sun, Z., Thomas, A. M., & Li, S. (2023) · Stem Cells International · doi:10.1155/2023/1109967 · Cited by 19

Experimental Models of HD and Reflection on Therapeutic Strategies

Kim, J., Bordiuk, O. L., & Ferrante, R. J. (2011) · International review of neurobiology · doi:10.1016/b978-0-12-381328-2.00016-x · Cited by 20

Mitochondrial and metabolic-based protective strategies in Huntington’s disease: the case of creatine and coenzyme Q

Naia, L., Ribeiro, M. J., & Rego, A. C. (2011) · Reviews in the Neurosciences · doi:10.1515/rns.2011.060 · Cited by 19

A transgenic minipig model of Huntington's disease shows early signs of behavioral and molecular pathologies

Askeland, G., Rodinová, M., Štufková, H., Dosoudilova, Z., Baxa, M., Šmatlíková, P., Bohuslavová, B., Klempíř, J., Nguyen, T. D., Kuśnierczyk, A., et al. (2018) · Disease Models & Mechanisms · doi:10.1242/dmm.035949 · Cited by 19

Remacemide--a novel potential antiepileptic drug.

Małek, R., Borowicz, K. K., Kimber-Trojnar, Z., Sobieszek, G., Piskorska, B., & Czuczwar, S. J. (2003) · PubMed · Cited by 19

Metabolomics: An Emerging “Omics” Platform for Systems Biology and Its Implications for Huntington Disease Research

Akyol, S., Ashrafi, N., Yılmaz, A., Türkoğlu, O., & Graham, S. F. (2023) · Metabolites · doi:10.3390/metabo13121203 · Cited by 20

Huntington’s disease: novel therapeutic perspectives hanging in the balance

Saavedra, A., Barriga, G. G.-D., Pérez‐Navarro, E., & Alberch, J. (2018) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2018.1465930 · Cited by 18

Automated Behavioral Phenotyping Reveals Presymptomatic Alterations in a SCA3 Genetrap Mouse Model

Hübener‐Schmid, J., Casadei, N., Teismann, P., Seeliger, M. W., Björkqvist, M., von Hörsten, S., Rieß, O., & Nguyen, H. P. (2012) · Journal of genetics and genomics/Journal of Genetics and Genomics · doi:10.1016/j.jgg.2012.04.009 · Cited by 16

Development of novel therapies for Huntington's disease: hope and challenge1

Qin, Z., Wang, J., & Gu, Z. (2005) · Acta Pharmacologica Sinica · doi:10.1111/j.1745-7254.2005.00520.x · Cited by 16

Endothelial Dysfunction in Huntington’s Disease: Pathophysiology and Therapeutic Implications

Hu, N., Chen, Z., Zhao, X., Peng, X., Wu, Y. S., Yang, K., & Sun, T. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26041432 · Cited by 15

Time-Course Analysis of Protein and Lipid Oxidation in the Brains of Yac128 Huntington's Disease Transgenic Mice

Brocardo, P. S., McGinnis, E., Christie, B. R., & Gil‐Mohapel, J. (2015) · Rejuvenation Research · doi:10.1089/rej.2015.1736 · Cited by 15

Neuroprotective Methodologies of Co-Enzyme Q10 Mediated Brain Hemorrhagic Treatment: Clinical and Pre-Clinical Findings

Rajdev, K., & Mehan, S. (2019) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527318666190610101144 · Cited by 15

Early Detection of Apathetic Phenotypes in Huntington’s Disease Knock-in Mice Using Open Source Tools

Minnig, S., Bragg, R. M., Tiwana, H. S., Solem, W. T., Hovander, W. S., Vik, E.-M. S., Hamilton, M., Legg, S. R. W., Shuttleworth, D. D., Coffey, S. R., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-20607-7 · Cited by 14

Dietary supplementation with peptides from sesame cake protect Caenorhabditis elegans from polyglutamine-induced toxicity

Ma, X., Li, J., Cui, X., Li, F., & Wang, Z. (2019) · Journal of Functional Foods · doi:10.1016/j.jff.2019.01.002 · Cited by 14

Huntington’s Disease-Like 2

Margolis, R. L., & Rudnicki, D. D. (2007) · Springer eBooks · doi:10.1007/978-3-540-71693-8_5 · Cited by 13

Lithium carbonate and coenzyme Q10 reduce cell death in a cell model of Machado-Joseph disease

Lopes‐Ramos, C. M., Pereira, T. C., Dogini, D. B., Gilioli, R., & Lopes‐Cendes, Í. (2016) · Brazilian Journal of Medical and Biological Research · doi:10.1590/1414-431x20165805 · Cited by 13

Hprt (CAG)146 mice: Age of onset of behavioral abnormalities, time course of neuronal intranuclear inclusion accumulation, neurotransmitter marker alterations, mitochondrial function markers, and susceptibility to 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine

Tallaksen‐Greene, S. J., Ordway, J. M., Crouse, A. B., Jackson, W. S., Detloff, P. J., & Albin, R. L. (2003) · The Journal of Comparative Neurology · doi:10.1002/cne.10855 · Cited by 13

The contribution of preclinical magnetic resonance imaging and spectroscopy to Huntington’s disease

Pérot, J., Brouillet, E., & Flament, J. (2024) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2024.1306312 · Cited by 12

Do glial cells play an anti-oxidative role in Huntington's disease?

Gao, Y., Chu, S., Li, J.-P., Zuo, W., Wen, Z.-L., He, W., Yan, J., & Chen, N. H. (2014) · Free Radical Research · doi:10.3109/10715762.2014.936432 · Cited by 12

The Complexity of Clinical Huntington’s Disease: Developments in Molecular Genetics, Neuropathology and Neuroimaging Biomarkers

Tippett, L. J., Waldvogel, H. J., Snell, R. G., Vonsattel, J., Young, A. B., & Faull, R. L. M. (2017) · Advances in neurobiology · doi:10.1007/978-3-319-57193-5_5 · Cited by 12

Huntington’s Disease

Pender, N. P., & Koroshetz, W. J. (2011) · Springer eBooks · doi:10.1007/978-1-84996-011-3_8 · Cited by 11

Plasma 8-hydroxy-2′-deoxyguanosine Levels in Huntington Disease and Healthy Controls Treated with Coenzyme Q10

Biglan, K., for the Huntington Study Group Pre2CARE Investigators, Dorsey, E. R., Evans, R. V. V., Ross, C. A., Hersch, S. M., Shoulson, I., Matson, W. R., & Kieburtz, K. D. (2012) · Journal of Huntington s Disease · doi:10.3233/jhd-2012-120007 · Cited by 12

Juvenile Huntington's disease: a case report and literature review.

Molón, L. R., Sáez, R. M. Y., & Alcocer, M. I. L. (2010) · Actas Españolas de Psiquiatría · Cited by 12

Methyltetrahydrofolate reductase polymorphism influences onset of Huntington’s disease

Brune, N., Andrich, J., Genčík, M., Carsten Saft, C., Müller, T., Valentin, S., Przuntek, H., & Epplen, J. T. (2004) · Journal of neural transmission. Supplementum · doi:10.1007/978-3-7091-0579-5_12 · Cited by 12

Huntington Disease

Wagner, L. A., Menalled, L., Goumeniouk, A. D., Brunner, D., & Leavitt, B. R. (2008) · Elsevier eBooks · doi:10.1016/b978-0-12-373861-5.00018-7 · Cited by 12

The Effects of Coenzyme Q10 Supplementation on Oxidative Status and Lipid Profile in Migraine Patients: A Randomized Double-Blinded Controlled Clinical Trial

Dahri, M., Sadeghi, A. S., Pahlavani, N., Nattagh‐Eshtivani, E., Hashemilar, M., Jafarabadi, M. A., Barghchi, H., & Tarighat‐Esfanjani, A. (2023) · Clinical Nutrition Research · doi:10.7762/cnr.2023.12.4.257 · Cited by 11

Current Therapeutic Advances in Patients and Experimental Models of Huntington's Disease

Brett, A., Rosenstock, T. R., & Rego, A. C. (2014) · Current Drug Targets · doi:10.2174/1389450114666131124140704 · Cited by 11

Cytotoxicity models of Huntington’s disease and relevance of hormetic mechanisms: A critical assessment of experimental approaches and strategies

Calabrese, E. J., Bhatia, T. N., Calabrese, V., Dhawan, G., Giordano, J., Hanekamp, Y. N., Kapoor, R., Kozumbo, W. J., & Leak, R. K. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.104371 · Cited by 12

Effects of coenzyme Q10 supplementation on the anthropometric variables, lipid profiles and liver enzymes in patients with non-alcoholic fatty liver disease

Jafarvand, E., Farhangi, M. A., Alipour, B., & Khoshbaten, M. (2015) · Bangladesh Journal of Pharmacology · doi:10.3329/bjp.v11i1.24513 · Cited by 11

Lipidomics of Huntington’s Disease: A Comprehensive Review of Current Status and Future Directions

Yılmaz, A., Akyol, S., Ashrafi, N., Saiyed, N., Türkoğlu, O., & Graham, S. F. (2025) · Metabolites · doi:10.3390/metabo15010010 · Cited by 10

Experimental and Clinical Strategies for Treating Spinocerebellar Ataxia Type 3

Wang, Z. (2017) · Neuroscience · doi:10.1016/j.neuroscience.2017.11.051 · Cited by 11

High-dose 1,25-dihydroxyvitamin D supplementation elongates the lifespan of Huntington's disease transgenic mice

Molnar, M. F., Maszlag-Török, R., Vágvölgyi-Sümegi, E., Vécsei, L., Klivènyi, P., & Szalárdy, L. (2016) · Acta Neurobiologiae Experimentalis · doi:10.21307/ane-2017-017 · Cited by 10

Mitochondria in neurodegeneration

Beal, M. F. (2002) · Springer eBooks · doi:10.1007/978-2-8178-0929-8_3 · Cited by 10

Melatonin is effective in attenuating cisplatin‐induced neurotoxicity

BAYRAKTAR, U. A., Arıhan, O., Atalay, Ö., Gök, M., Çiçek, Ç., Bodur, E., & Tuncer, M. (2022) · Journal of Biochemical and Molecular Toxicology · doi:10.1002/jbt.23075 · Cited by 9

The plasma membrane redox system in Alzheimer's disease

Adlard, P. A., & Bush, A. I. (2010) · Experimental Neurology · doi:10.1016/j.expneurol.2010.12.009 · Cited by 9

Oral Repeated-Dose Toxicity Studies of Coenzyme Q10 in Beagle Dogs

Yerramilli-Rao, P., Beal, M. F., Watanabe, D., Kieburtz, K. D., de Blieck, E. A., Kitano, M., Hosoe, K., Funahashi, I., & Cudkowicz, M. (2012) · International Journal of Toxicology · doi:10.1177/1091581811425256 · Cited by 9

Coenzyme Q10 and remacemide hydrochloride ameliorate motor deficits in a Huntington's disease transgenic mouse model

Schilling, G., Coonfield, M. L., Ross, C. A., & Borchelt, D. R. (2001) · Neuroscience Letters · doi:10.1016/s0304-3940(01)02326-6 · Cited by 151

Dose ranging and efficacy study of high-dose coenzyme Q10 formulations in Huntington's disease mice

Smith, K. M., Matson, S., Matson, W. R., Cormier, K., Del Signore, S. J., Hagerty, S. W., Stack, E. C., Ryu, H., & Ferrante, R. J. (2006) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2006.03.004 · Cited by 127

A randomized, placebo-controlled trial of coenzyme Q 10 and remacemide in Huntington’s disease

The Huntington Study Group (2001) · Neurology · doi:10.1212/wnl.57.3.397 · Cited by 312

Targeting energy metabolism in Huntington's disease

Walker, F. O., & Raymond, L. A. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16739-1 · Cited by 21

Combination therapy using minocycline and coenzyme Q10 in R6/2 transgenic Huntington's disease mice

Stack, E. C., Smith, K. M., Ryu, H., Cormier, K., Chen, M., Hagerty, S. W., Del Signore, S. J., Cudkowicz, M. E., Friedlander, R. M., & Ferrante, R. J. (2006) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2005.11.002 · Cited by 114